ABBV vs JNJ vs MRK
161 measures in 16 categories, one definition each, computed from filings and market data.
ABBV66.6
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$285.42 +0.71%$504.4B mkt cap
Score DNA
JNJ64.2
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$255.56 +0.90%$615.9B mkt cap
Score DNA
MRK48.9
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
$145.97 +0.52%$360.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
ABBV JNJ MRK · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 1 | 8 | 4 |
| Last Congress purchase | 2026-05-01 | 2026-09-25 | 2026-08-19 |
| 13F net change in holders | +124 | +46 | +47 |
| ETFs adding shares, 30d | 1,804 | 1,797 | 1,877 |
| ETFs trimming, 30d | 1,578 | 1,601 | 1,581 |
| Net ETF funds, 30d | +226 | +196 | +296 |
Valuation
16 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| P/E (TTM) | 79.9x
90th
|
29.3x
50th
|
113.5x
100th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 1.45
60th
|
— |
| Price / sales | 7.8x
91st
|
6.3x
73rd
|
5.4x
55th
|
| Price / book | — | 7.2x
60th
|
8.6x
70th
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 26.4x
82nd
|
32.9x
91st
|
22.4x
55th
|
| Price / operating cash flow | 25.9x
82nd
|
26.0x
91st
|
18.0x
55th
|
| Enterprise value | $568.6B
82nd
|
$644.2B
91st
|
$406.9B
73rd
|
| EV / sales | 8.8x
91st
|
6.6x
64th
|
6.1x
55th
|
| EV / EBITDA | 26.8x
73rd
|
19.1x
55th
|
29.2x
82nd
|
| EV / EBIT | 42.7x
90th
|
24.8x
50th
|
56.4x
100th
|
| EV / free cash flow | 29.8x
82nd
|
34.4x
91st
|
25.3x
55th
|
| Earnings yield | 1.3%
18th
|
3.4%
55th
|
0.9%
9th
|
| FCF yield | 3.8%
18th
|
3.0%
9th
|
4.5%
45th
|
| Operating cash flow yield | 3.9%
18th
|
3.8%
9th
|
5.5%
45th
|
| Graham number (per share) | — | $82.19
67th
|
$22.13
22nd
|
Profitability (TTM)
12 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Gross margin | 71.5%
45th
|
68.8%
18th
|
75.4%
73rd
|
| EBITDA margin | 32.9%
55th
|
34.4%
73rd
|
20.9%
27th
|
| Operating margin | 29.3%
73rd
|
26.8%
64th
|
15.3%
18th
|
| EBIT margin | 20.7%
45th
|
26.5%
64th
|
10.8%
18th
|
| Net margin | 9.8%
45th
|
21.5%
73rd
|
4.8%
18th
|
| NOPAT margin | 21.3%
55th
|
22.4%
64th
|
8.1%
9th
|
| FCF margin | 29.7%
82nd
|
19.1%
27th
|
24.2%
45th
|
| Operating cash flow margin | 30.3%
64th
|
24.2%
27th
|
30.0%
55th
|
| R&D / revenue | 15.1%
9th
|
15.4%
18th
|
43.7%
100th
|
| SG&A / revenue | 22.8%
55th
|
25.7%
73rd
|
16.6%
18th
|
| Stock comp / revenue | 1.5%
100th
|
1.4%
82nd
|
1.0%
45th
|
| Effective tax rate | 27.4%
82nd
|
16.5%
27th
|
46.7%
91st
|
Returns on capital
11 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| ROE (on average equity) | — | 25.7%
60th
|
7.0%
30th
|
| ROA | 4.6%
45th
|
10.7%
82nd
|
2.6%
27th
|
| ROIC | 23.5%
91st
|
19.4%
73rd
|
6.1%
27th
|
| ROCE | 14.2%
45th
|
17.8%
64th
|
7.1%
27th
|
| Return on tangible assets | 9.8%
45th
|
13.2%
64th
|
5.8%
27th
|
| Cash ROIC (OCF / invested capital) | 33.4%
82nd
|
20.9%
36th
|
22.5%
55th
|
| Gross profitability (GP / assets) | 34.1%
55th
|
33.1%
36th
|
38.9%
64th
|
| ROIC, 3-yr average | 10.8%
55th
|
24.8%
91st
|
9.7%
45th
|
| ROIC, 5-yr average | — | 24.2%
89th
|
16.2%
56th
|
| ROE, 5-yr average | — | 29.6%
67th
|
23.8%
56th
|
| Incremental ROIC | -202.7%
18th
|
62.9%
64th
|
-29.1%
36th
|
Growth
17 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Revenue growth (TTM YoY) | 10.4%
91st
|
8.1%
64th
|
4.5%
45th
|
| Revenue growth (QoQ) | 13.3%
82nd
|
5.2%
27th
|
2.0%
9th
|
| Revenue CAGR, 3 yr | 4.7%
64th
|
4.4%
45th
|
4.5%
55th
|
| Revenue CAGR, 5 yr | 3.7%
55th
|
1.9%
18th
|
7.9%
64th
|
| Gross profit CAGR, 3 yr | 6.0%
55th
|
4.1%
36th
|
5.9%
45th
|
| Operating income CAGR, 3 yr | 2.8%
30th
|
5.8%
40th
|
16.7%
70th
|
| Net income growth (TTM YoY) | 67.5%
80th
|
-7.2%
40th
|
-80.7%
0th
|
| Net income CAGR, 3 yr | -10.1%
30th
|
17.2%
70th
|
0.7%
40th
|
| EPS growth (TTM YoY) | 67.6%
70th
|
-8.0%
40th
|
-80.3%
0th
|
| EPS CAGR, 3 yr | -10.1%
30th
|
20.1%
70th
|
1.6%
40th
|
| EPS CAGR, 5 yr | -1.0%
44th
|
5.3%
56th
|
-10.2%
33rd
|
| FCF growth (TTM YoY) | 4.7%
50th
|
14.1%
80th
|
9.1%
60th
|
| FCF CAGR, 3 yr | -8.3%
0th
|
8.7%
45th
|
14.0%
64th
|
| Operating cash flow CAGR, 3 yr | -8.6%
0th
|
7.5%
55th
|
9.8%
64th
|
| Book value CAGR, 3 yr | — | 6.8%
56th
|
3.6%
44th
|
| Dividend CAGR, 3 yr | 1.8%
50th
|
4.0%
70th
|
2.0%
60th
|
| Sustainable growth rate | — | 10.3%
44th
|
-11.3%
0th
|
Margin history & stability
7 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Gross margin, 3-yr average | 69.5%
45th
|
68.3%
36th
|
75.9%
73rd
|
| Operating margin, 3-yr average | 24.0%
55th
|
26.3%
82nd
|
24.0%
64th
|
| Net margin, 3-yr average | 8.7%
27th
|
30.1%
100th
|
17.5%
73rd
|
| FCF margin, 3-yr average | 31.1%
91st
|
20.2%
36th
|
22.8%
55th
|
| Revenue stability (0-1) | 0.72
45th
|
0.39
18th
|
0.93
82nd
|
| Earnings stability (0-1) | 0.30
55th
|
0.11
36th
|
0.00
9th
|
| Margin stability (0-1) | 0.93
45th
|
0.99
100th
|
0.95
55th
|
Liquidity (latest quarter)
7 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Cash & short-term investments | $6.6B
36th
|
$20.8B
100th
|
$7.1B
45th
|
| Net cash (− = net debt) | −$64.3B
0th
|
−$28.3B
64th
|
−$46.8B
18th
|
| Working capital | −$8.0B
0th
|
$4.9B
55th
|
$8.9B
73rd
|
| Current ratio | 0.81
0th
|
1.09
27th
|
1.32
55th
|
| Quick ratio | 0.69
18th
|
0.81
27th
|
1.10
64th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.16
9th
|
0.38
73rd
|
0.26
36th
|
| Defensive interval (days) | 274 days
45th
|
361 days
73rd
|
178 days
9th
|
Leverage & solvency (latest quarter)
13 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Total debt | $70.8B
100th
|
$49.0B
55th
|
$53.9B
64th
|
| Debt / equity | — | 0.58
10th
|
1.29
50th
|
| Net debt / equity | — | 0.33
0th
|
1.12
50th
|
| Debt / assets | 52.4%
73rd
|
24.4%
0th
|
41.5%
55th
|
| Debt / capital | — | 36.6%
10th
|
56.2%
50th
|
| Debt / EBITDA | 3.34
55th
|
1.45
9th
|
3.87
64th
|
| Net debt / EBITDA | 3.03
55th
|
0.84
0th
|
3.36
64th
|
| Interest coverage (EBIT / interest) | 4.6x
36th
|
33.1x
91st
|
5.7x
55th
|
| Cash interest coverage | 6.7x
27th
|
30.2x
100th
|
15.8x
82nd
|
| Debt payback (years of OCF) | 3.6 yrs
73rd
|
2.1 yrs
18th
|
2.7 yrs
45th
|
| Liabilities / assets | 104.3%
100th
|
57.7%
27th
|
67.7%
45th
|
| IS credit model rating | BB- | AA | A- |
| Implied credit spread (bps) | 550
91st
|
80
0th
|
175
36th
|
Efficiency
11 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Asset turnover | 0.47
36th
|
0.50
55th
|
0.54
64th
|
| Fixed asset turnover | 11.11
100th
|
4.15
45th
|
2.58
0th
|
| Inventory turnover | 3.6
91st
|
2.2
55th
|
2.5
73rd
|
| Receivables turnover | 4.9
45th
|
5.3
73rd
|
5.4
82nd
|
| Days sales outstanding | 75 days
55th
|
69 days
27th
|
67 days
18th
|
| Days inventory outstanding | 100 days
9th
|
166 days
45th
|
146 days
27th
|
| Days payables outstanding | 646 days
91st
|
109 days
36th
|
88 days
18th
|
| Cash conversion cycle (days) | −471 days
0th
|
126 days
55th
|
125 days
45th
|
| Capex / revenue | 0.6%
0th
|
5.1%
60th
|
5.9%
70th
|
| Capex / depreciation | 0.05
0th
|
0.64
80th
|
0.58
60th
|
| Operating expense ratio | 36.9%
18th
|
39.8%
36th
|
77.6%
91st
|
Cash flow & earnings quality
7 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Operating cash flow / net income | 3.09
60th
|
1.13
10th
|
6.29
100th
|
| FCF / net income | 3.02
80th
|
0.89
10th
|
5.06
100th
|
| FCF / operating cash flow | 97.9%
100th
|
78.9%
30th
|
80.4%
40th
|
| Capex / operating cash flow | 2.1%
0th
|
21.1%
70th
|
19.6%
60th
|
| Accruals ratio | -9.7%
18th
|
-1.4%
91st
|
-13.6%
9th
|
| Sloan accruals ratio | -3.9%
36th
|
-1.6%
64th
|
-7.1%
9th
|
| Earnings quality score (0-1) | 0.75
0th
|
1.00
30th
|
0.75
0th
|
Scores & forensic checks
15 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| IS score | 67
64th
|
64
45th
|
49
36th
|
| IS profitability | 62
45th
|
85
64th
|
28
9th
|
| IS growth | 76
91st
|
42
55th
|
24
27th
|
| IS value | 32
9th
|
42
45th
|
36
18th
|
| IS momentum | 91
91st
|
67
55th
|
58
36th
|
| IS risk (safety) | 50
9th
|
100
91st
|
90
64th
|
| IS quality | 72
45th
|
84
91st
|
55
18th
|
| IS balance sheet | 26
9th
|
69
100th
|
45
45th
|
| IS earnings quality | 59
18th
|
74
100th
|
54
9th
|
| IS cash flow | 77
82nd
|
65
45th
|
71
73rd
|
| Piotroski F-score (0-9) | 7
45th
|
7
45th
|
4
9th
|
| Altman Z-score | 2.4
27th
|
5.3
91st
|
3.6
73rd
|
| Beneish M-score | −2.82
27th
|
−2.49
91st
|
−2.94
18th
|
| Ohlson O-score | −7.50
73rd
|
−9.00
9th
|
−7.82
64th
|
| IS credit score | 40
9th
|
88
100th
|
66
64th
|
Size (TTM)
8 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| Market cap | $504.4B
82nd
|
$615.9B
91st
|
$360.1B
73rd
|
| Revenue | $64.4B
73rd
|
$97.9B
100th
|
$66.5B
82nd
|
| EBITDA | $21.2B
73rd
|
$33.7B
91st
|
$13.9B
36th
|
| Net income | $6.3B
45th
|
$21.0B
91st
|
$3.2B
27th
|
| Free cash flow | $19.1B
91st
|
$18.7B
82nd
|
$16.1B
73rd
|
| Total assets | $135.1B
73rd
|
$201.1B
91st
|
$129.8B
64th
|
| Shareholders' equity | −$5.9B
0th
|
$85.0B
91st
|
$41.9B
73rd
|
| Employees | 57,000
55th
|
141,700
100th
|
74,000
64th
|
Price performance
9 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| 1 day | +0.7% | +0.9% | +0.5% |
| 1 week | +3.9% | −2.2% | +0.2% |
| 1 month | +8.1% | −5.4% | −0.8% |
| 3 months | +12.7% | +2.7% | +17.3% |
| 6 months | +37.0% | +9.1% | +22.6% |
| Year to date | +25.5% | +23.9% | +37.1% |
| 1 year | +26.2% | +34.5% | +75.0% |
| 3 years, cumulative | +107.1% | +75.4% | +51.5% |
| 5 years, cumulative | +201.3% | +79.7% | +106.7% |
Technicals
4 measures| Measure | ABBV | JNJ | MRK |
|---|---|---|---|
| RSI 14 | 71.1 | 43.8 | 52.0 |
| From 52-week high | −2.0% | −9.1% | −7.0% |
| From 52-week low | +49.6% | +39.3% | +79.5% |
| Beta | 0.28 | 0.23 | 0.22 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17